{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:40:45Z","timestamp":1782891645939,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11523-024-01123-3","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T06:28:25Z","timestamp":1737095305000},"page":"183-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bosutinib for the Treatment of CML\u2014Using it Safely: a Podcast"],"prefix":"10.1007","volume":"20","author":[{"given":"Jeffrey H.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"issue":"7","key":"1123_CR1","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","volume":"36","author":"TH Br\u00fcmmendorf","year":"2022","unstructured":"Br\u00fcmmendorf TH, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825\u201333.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"1123_CR2","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1182\/blood-2018-99-110152","volume":"132","author":"TH Br\u00fcmmendorf","year":"2018","unstructured":"Br\u00fcmmendorf TH, et al. Impact of diarrhea on health-related quality of life: analysis of the phase 3 BFORE trial of bosutinib vs imatinib for newly diagnosed chronic phase chronic myeloid leukemia. Blood. 2018;132(Suppl 1):4264\u20134264.","journal-title":"Blood"},{"issue":"3","key":"1123_CR3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1123_CR4","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00432-019-02894-3","volume":"145","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, et al. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. J Cancer Res Clin Oncol. 2019;145(6):1589\u201399.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"16_suppl","key":"1123_CR5","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1200\/JCO.2022.40.16_suppl.7049","volume":"40","author":"JE Cortes","year":"2022","unstructured":"Cortes JE, et al. Bosutinib (BOS) in newly diagnosed chronic myeloid leukemia (CML): gastrointestinal (GI), liver, effusion, and renal safety characterization in the BFORE trial. J Clin Oncol. 2022;40(16_suppl):7049.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"1123_CR6","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/JCO.2021.39.15_suppl.7009","volume":"39","author":"C Gambacorti-Passerini","year":"2021","unstructured":"Gambacorti-Passerini C, et al. Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): final 10-year results of a phase 1\/2 study. J Clin Oncol. 2021;39(15_suppl):7009.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1123_CR7","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome\u2014positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567\u201376.","journal-title":"Blood"},{"issue":"12","key":"1123_CR8","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","volume":"91","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib. Am J Hematol. 2016;91(12):1206\u201314.","journal-title":"Am J Hematol"},{"issue":"12","key":"1123_CR9","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.3324\/haematol.2022.281944","volume":"108","author":"JE Cortes","year":"2023","unstructured":"Cortes JE, et al. Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I\/II study. Haematologica. 2023;108(12):3454\u20139.","journal-title":"Haematologica"},{"issue":"8","key":"1123_CR10","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","volume":"103","author":"C Gambacorti-Passerini","year":"2018","unstructured":"Gambacorti-Passerini C, et al. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study. Haematologica. 2018;103(8):1298\u2013307.","journal-title":"Haematologica"},{"issue":"15","key":"1123_CR11","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood. 2012;119(15):3403\u201312.","journal-title":"Blood"},{"key":"1123_CR12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1182\/blood-2021-150352","volume":"138","author":"C Gambacorti-Passerini","year":"2021","unstructured":"Gambacorti-Passerini C, et al. Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the Byond trial. Blood. 2021;138:1475.","journal-title":"Blood"},{"issue":"8","key":"1123_CR13","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34(8):2125\u201337.","journal-title":"Leukemia"},{"issue":"1","key":"1123_CR14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41375-023-02080-y","volume":"38","author":"G Rosti","year":"2024","unstructured":"Rosti G, et al. Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study. Leukemia. 2024;38(1):126\u201335.","journal-title":"Leukemia"},{"key":"1123_CR15","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107481","volume":"139","author":"BD Smith","year":"2024","unstructured":"Smith BD, et al. Efficacy and safety of bosutinib in patients treated with prior imatinib and\/or dasatinib and\/or nilotinib: subgroup analyses from the phase 4 BYOND study. Leuk Res. 2024;139: 107481.","journal-title":"Leuk Res"},{"issue":"1","key":"1123_CR16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Br\u00fcmmendorf","year":"2015","unstructured":"Br\u00fcmmendorf TH, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015;168(1):69\u201381.","journal-title":"Br J Haematol"},{"issue":"28","key":"1123_CR17","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486\u201392.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1123_CR18","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.23788","volume":"89","author":"C Gambacorti-Passerini","year":"2014","unstructured":"Gambacorti-Passerini C, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014;89(10):947\u201353.","journal-title":"Am J Hematol"},{"issue":"10","key":"1123_CR19","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clml.2017.06.001","volume":"17","author":"JE Cortes","year":"2017","unstructured":"Cortes JE, et al. Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias. Clin Lymphoma Myeloma Leuk. 2017;17(10):684-695.e6.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"1123_CR20","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/ejh.13608","volume":"106","author":"JE Cortes","year":"2021","unstructured":"Cortes JE, et al. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. Eur J Haematol. 2021;106(6):808\u201320.","journal-title":"Eur J Haematol"},{"key":"1123_CR21","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100968","volume":"56","author":"JH Lipton","year":"2022","unstructured":"Lipton JH, et al. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia\u2014what to look for when treatment-free remission is not an option. Blood Rev. 2022;56: 100968.","journal-title":"Blood Rev"},{"issue":"5","key":"1123_CR22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.clml.2024.01.005","volume":"24","author":"HM Kantarjian","year":"2024","unstructured":"Kantarjian HM, et al. A review of the therapeutic role of bosutinib in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2024;24(5):285\u201397.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1123_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-022-03446-1","volume":"117","author":"Z Narl\u0131 \u00d6zdemir","year":"2023","unstructured":"Narl\u0131 \u00d6zdemir Z, et al. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities. Int J Hematol. 2023;117(1):3\u201315.","journal-title":"Int J Hematol"},{"issue":"6","key":"1123_CR24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691\u2013709.","journal-title":"Am J Hematol"},{"issue":"1","key":"1123_CR25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/ejh.13775","volume":"109","author":"S Claudiani","year":"2022","unstructured":"Claudiani S, et al. A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. Eur J Haematol. 2022;109(1):90\u20139.","journal-title":"Eur J Haematol"},{"issue":"15","key":"1123_CR26","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1200\/JCO.2021.39.15_suppl.7037","volume":"39","author":"TH Br\u00fcmmendorf","year":"2021","unstructured":"Br\u00fcmmendorf TH, et al. The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2021;39(15):7037.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1123_CR27","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","volume":"111","author":"H Konig","year":"2008","unstructured":"Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606. Blood. 2008;111(4):2329\u201338.","journal-title":"Blood"},{"issue":"3","key":"1123_CR28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","volume":"23","author":"LL Remsing Rix","year":"2009","unstructured":"Remsing Rix LL, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23(3):477\u201385.","journal-title":"Leukemia"},{"key":"1123_CR29","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.1016\/S2152-2650(23)01154-0","volume":"23","author":"J Clements","year":"2023","unstructured":"Clements J, et al. CML-562 the importance of quality of survivorship: US results from the chronic myeloid leukemia (CML) survey on unmet needs (SUN). Clin Lymph Myeloma Leuk. 2023;23:S348.","journal-title":"Clin Lymph Myeloma Leuk"},{"issue":"S3","key":"1123_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000969576.83189.62","volume":"7","author":"F Lang","year":"2023","unstructured":"Lang F, et al. P668: chronic myeloid leukemia survey on unmet needs (Cml Sun): balancing tolerability and efficacy goals of patients and physicians through shared treatment decision-making. Hemasphere. 2023;7(S3): e8318962. https:\/\/doi.org\/10.1097\/01.HS9.0000969576.83189.62.","journal-title":"Hemasphere"},{"issue":"3","key":"1123_CR31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cncr.31082","volume":"124","author":"HM Kantarjian","year":"2018","unstructured":"Kantarjian HM, et al. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer. 2018;124(3):587\u201395.","journal-title":"Cancer"},{"issue":"Suppl 1","key":"1123_CR32","doi-asserted-by":"crossref","first-page":"12194","DOI":"10.1182\/blood-2022-164607","volume":"140","author":"S Isfort","year":"2022","unstructured":"Isfort S, et al. Health-related quality of life of CML patients under 2nd or 3rd line bosutinib is not impaired significantly by gastrointestinal toxicity (GI Tox) but influenced by sex\u2014results from a subanalysis of the Bosutinib Dose Optimization (BODO) study (CML-VII) trial of the German CML study group. Blood. 2022;140(Suppl 1):12194\u20136.","journal-title":"Blood"},{"issue":"6","key":"1123_CR33","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-020-04018-1","volume":"99","author":"TH Br\u00fcmmendorf","year":"2020","unstructured":"Br\u00fcmmendorf TH, et al. Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia. Ann Hematol. 2020;99(6):1241\u20139.","journal-title":"Ann Hematol"},{"issue":"10","key":"1123_CR34","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00277-023-05394-0","volume":"102","author":"S Isfort","year":"2023","unstructured":"Isfort S, et al. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study. Ann Hematol. 2023;102(10):2741\u201352.","journal-title":"Ann Hematol"},{"issue":"Suppl 1","key":"1123_CR35","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood-2023-174594","volume":"142","author":"H Ureshino","year":"2023","unstructured":"Ureshino H, et al. Lower-initiating dose of bosutinib for resistant or intolerant to prior therapy chronic myeloid leukemia patients (BOGI trial): a single-arm, multicenter, phase ii trial. Blood. 2023;142(Suppl 1):3179\u20133179.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1123_CR36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2019-127514","volume":"134","author":"F Castagnetti","year":"2019","unstructured":"Castagnetti F, et al. Dose optimization in elderly CML patients treated with bosutinib after intolerance or failure of first-line tyrosine kinase inhibitors. Blood. 2019;134(Suppl 1):496\u2013496.","journal-title":"Blood"},{"key":"1123_CR37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40164-018-0101-1","volume":"7","author":"A Mita","year":"2018","unstructured":"Mita A, et al. Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia. Exp Hematol Oncol. 2018;7:9.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"1123_CR38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hon.2851","volume":"39","author":"R Latagliata","year":"2021","unstructured":"Latagliata R, et al. Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant\/intolerant to previous tyrosine-kinase inhibitors. Hematol Oncol. 2021;39(3):401\u20138.","journal-title":"Hematol Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01123-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01123-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01123-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T12:50:58Z","timestamp":1743079858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01123-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01123-3","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"16 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This podcast was sponsored by Pfizer. No funding was provided for the authoring of this review. The authors received no honoraria related to the development of this publication. Medical writing support was provided by Anne Marie McGonigal, PhD, CMPP, of Engage Scientific Solutions and funded by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jeffrey Lipton has been a consultant for Bristol Myers Squibb, Novartis, Pfizer, and Takeda (currently only with Pfizer and Takeda); has received research funding from Bristol Myers Squibb, Novartis, Pfizer, and Takeda and honoraria from Bristol Myers Squibb, Novartis, Incyte, Pfizer, and Takeda. Jorge E Cortes has served as a consultant for Amphivena Therapeutics, Astellas Pharma, Bio-Path Holdings Inc, BiolineRx, Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, and Takeda and has received research funding from Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Immunogen, Jazz Pharmaceuticals, Merus, Novartis, Pfizer, Sun Pharma, Takeda, Tolero Pharmaceuticals, and Tovagene.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"Jeffrey H Lipton and Jorge E Cortes made substantial contributions to the article concept\/design, critically reviewed and revised the manuscript drafts, and provided final approval of the article and enhanced content as submitted.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}